HK1255046A1 - 粒细胞巨噬细胞集落刺激因子的拮抗剂的用途 - Google Patents

粒细胞巨噬细胞集落刺激因子的拮抗剂的用途 Download PDF

Info

Publication number
HK1255046A1
HK1255046A1 HK18114170.3A HK18114170A HK1255046A1 HK 1255046 A1 HK1255046 A1 HK 1255046A1 HK 18114170 A HK18114170 A HK 18114170A HK 1255046 A1 HK1255046 A1 HK 1255046A1
Authority
HK
Hong Kong
Prior art keywords
pain
csf
amino acid
acid sequence
seq
Prior art date
Application number
HK18114170.3A
Other languages
English (en)
Chinese (zh)
Inventor
约翰‧艾伦‧汉密尔顿
約翰‧艾倫‧漢密爾頓
安德鲁‧大卫‧库克
安德魯‧大衛‧庫克
Original Assignee
墨尔本大学
墨爾本大學
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 墨尔本大学, 墨爾本大學 filed Critical 墨尔本大学
Publication of HK1255046A1 publication Critical patent/HK1255046A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
HK18114170.3A 2008-12-22 2018-11-07 粒细胞巨噬细胞集落刺激因子的拮抗剂的用途 HK1255046A1 (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13968708P 2008-12-22 2008-12-22
US61/139,687 2008-12-22
US16449109P 2009-03-30 2009-03-30
US61/164,491 2009-03-30

Publications (1)

Publication Number Publication Date
HK1255046A1 true HK1255046A1 (zh) 2019-08-02

Family

ID=42286785

Family Applications (2)

Application Number Title Priority Date Filing Date
HK18114170.3A HK1255046A1 (zh) 2008-12-22 2018-11-07 粒细胞巨噬细胞集落刺激因子的拮抗剂的用途
HK18114356.9A HK1255227A1 (en) 2008-12-22 2018-11-09 Pain treatment

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK18114356.9A HK1255227A1 (en) 2008-12-22 2018-11-09 Pain treatment

Country Status (12)

Country Link
US (3) US8475796B2 (enExample)
EP (2) EP2387418B1 (enExample)
JP (3) JP5674677B2 (enExample)
KR (1) KR101761324B1 (enExample)
CN (2) CN102256621B (enExample)
AU (2) AU2009329811B2 (enExample)
BR (1) BRPI0918103A2 (enExample)
CA (1) CA2747206C (enExample)
ES (2) ES2685895T3 (enExample)
HK (2) HK1255046A1 (enExample)
RU (2) RU2712166C2 (enExample)
WO (1) WO2010071923A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010071923A1 (en) * 2008-12-22 2010-07-01 The University Of Melbourne Pain treatment
AU2009329814B2 (en) 2008-12-22 2015-06-18 The University Of Melbourne Osteoarthritis treatment
KR20210021153A (ko) * 2012-09-20 2021-02-24 모르포시스 아게 류마티스 관절염에 대한 치료
CN109999195A (zh) * 2012-09-20 2019-07-12 莫弗系统股份公司 类风湿关节炎的治疗
JP6339578B2 (ja) * 2012-10-31 2018-06-06 タケダ・ゲー・エム・ベー・ハーＴａｋｅｄａ ＧｍｂＨ Ｇｍ−ｃｓｆ中和化合物を含む凍結乾燥製剤
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res Munich Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
WO2014138862A1 (en) * 2013-03-14 2014-09-18 John Schrader Human monoclonal antibodies that neutralize bioactivity of granulocyte macrophage colony-stimulating factor and methods and uses thereof
CN105705518A (zh) 2013-08-30 2016-06-22 塔科达有限责任公司 用于治疗类风湿性关节炎或作为镇痛药的中和gm-csf的抗体
JP7256116B2 (ja) 2016-09-19 2023-04-11 アイ－エムエービー バイオファーマ （ハンジョウ） カンパニー リミテッド 抗ｇｍ－ｃｓｆ抗体およびその使用
CN107840885B (zh) * 2016-09-19 2020-11-10 天境生物科技(上海)有限公司 Gm-csf抗体及其用途
CN120093288B (zh) * 2025-05-08 2025-07-11 中国农业大学烟台研究院 一种牲畜生理行为监测方法及系统

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH27534A (en) * 1989-07-14 1993-08-18 Schering Corp Antoganists of gm-csf derived from the carboxyl terminus
JP3267966B2 (ja) 1989-08-11 2002-03-25 アムラド・コーポレイション・リミテッド 顆粒球―マクロファージコロニー刺激因子受容体およびその誘導体における改良
US5747032A (en) 1990-08-10 1998-05-05 Amrad Corporation Limited Monoclonal antibody to human granulocyte macrophage colony stimulating factor
EP0673389A1 (en) * 1992-11-19 1995-09-27 Dana Farber Cancer Institute Antibodies for gm-csf receptor and uses thereof
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
AUPP525198A0 (en) 1998-08-13 1998-09-03 Medvet Science Pty. Ltd. Monoclonal antibody inhibitor of GM-CSF, IL-3 and IL-5 and other cytokines and uses thereof
US7108852B2 (en) 2000-03-20 2006-09-19 Warner-Lambert Company Llc Methods of treating inflammation using antibodies to M-CSF
US7455836B2 (en) 2000-05-08 2008-11-25 The University Of Melbourne Method of treatment and agents useful for same
SE0102067D0 (sv) * 2001-06-11 2001-06-11 A & Science Invest Ab Prevention of neovascularization of intervertebral discs and/or of tissues with local inflammation
JP2005507915A (ja) 2001-10-26 2005-03-24 ノバルティス アクチエンゲゼルシャフト 変形性関節症の処置方法およびその組成物
US7381801B2 (en) 2002-02-13 2008-06-03 Ludwig Institute For Cancer Research Chimerized GM-CSF antibodies
AU2002950957A0 (en) * 2002-08-23 2002-09-12 The Walter And Eliza Hall Institute Of Medical Research A method of treatment and prophylaxis
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
US20040241755A1 (en) 2003-06-02 2004-12-02 Pfizer Inc. Human cell assay to determine effect of sample compounds on Col2 enhancer expression
JP4825667B2 (ja) 2004-03-31 2011-11-30 一和 中尾 関節炎症治療剤又は予防剤
DE602004021773D1 (de) 2004-05-05 2009-08-13 Micromet Ag Herstellung eines einkettigen fv Antikörperfragments
UA94403C2 (ru) 2005-04-18 2011-05-10 Микромет Аг Человеческое моноклональное антитело, которое нейтрализует gm-csf
SI3620171T1 (sl) 2005-05-18 2022-09-30 Morphosys Ag Protitelesa proti GM-CSF in uporabe zanje
JP4736037B2 (ja) 2005-10-26 2011-07-27 株式会社イーベック ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分
EA200801166A1 (ru) 2005-12-01 2008-12-30 Домантис Лимитед Форматы конкурентного доменного антитела, которые связываются с рецептором интерлейкина 1 первого типа
WO2007092939A2 (en) * 2006-02-08 2007-08-16 Morphotek, Inc. Antigenic gm-csf peptides and antibodies to gm-csf
CA2647449C (en) 2006-03-27 2017-05-16 Medimmune Limited Binding member for gm-csf receptor
US7741273B2 (en) 2006-04-13 2010-06-22 Warsaw Orthopedic, Inc. Drug depot implant designs
EP2402013A1 (en) 2006-11-21 2012-01-04 Kalobios Pharmaceuticals, Inc. Methods of Treating Chronic Inflammatory Diseases using a GM-CSF Antagonist
WO2008080134A2 (en) 2006-12-22 2008-07-03 Rigel Pharmaceuticals, Inc. 4-amin0-2- (hetero) arylamino-5- (hetero) arylthiazoles useful as axl inhibitors
WO2008141391A1 (en) 2007-05-23 2008-11-27 Crc For Asthma And Airways Ltd Neutralizing antibodies
TW200918553A (en) 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
WO2009062238A1 (en) 2007-11-12 2009-05-22 Crc For Asthma And Airways Ltd Epitope for neutralizing antibodies
CN104072613A (zh) 2007-11-13 2014-10-01 Evec股份有限公司 与hGM-CSF结合的单克隆抗体及包含它的药物组合物
EA201001691A1 (ru) 2008-04-28 2011-10-31 Калобайос Фармасьютикалз, Инк. Антитела к гранулоцитарно-макрофагальному колониестимулирующему фактору
WO2010071923A1 (en) 2008-12-22 2010-07-01 The University Of Melbourne Pain treatment
AU2009329814B2 (en) 2008-12-22 2015-06-18 The University Of Melbourne Osteoarthritis treatment
SG175305A1 (en) 2009-04-23 2011-11-28 Theraclone Sciences Inc Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies

Also Published As

Publication number Publication date
EP2387418A4 (en) 2013-07-17
EP2387418B1 (en) 2018-06-13
ES2685895T3 (es) 2018-10-15
AU2016200267B2 (en) 2017-09-07
HK1255227A1 (en) 2019-08-09
EP3381471C0 (en) 2024-03-20
US9834599B2 (en) 2017-12-05
CN102256621A (zh) 2011-11-23
US8475796B2 (en) 2013-07-02
US20160311896A1 (en) 2016-10-27
JP2017149740A (ja) 2017-08-31
RU2016102346A3 (enExample) 2019-07-29
US20130243791A1 (en) 2013-09-19
RU2016102346A (ru) 2018-11-20
AU2016200267A1 (en) 2016-02-11
JP6147704B2 (ja) 2017-06-14
RU2630969C2 (ru) 2017-09-15
CN102256621B (zh) 2017-12-12
US9352034B2 (en) 2016-05-31
AU2009329811B2 (en) 2016-02-25
KR20110117659A (ko) 2011-10-27
AU2009329811A1 (en) 2010-07-01
ES2978209T3 (es) 2024-09-09
JP5674677B2 (ja) 2015-02-25
CA2747206C (en) 2018-04-24
US20110287027A1 (en) 2011-11-24
RU2011127333A (ru) 2013-01-27
CA2747206A1 (en) 2010-07-01
EP3381471A1 (en) 2018-10-03
CN108014335A (zh) 2018-05-11
EP3381471B1 (en) 2024-03-20
EP2387418A1 (en) 2011-11-23
JP2012512814A (ja) 2012-06-07
RU2712166C2 (ru) 2020-01-24
JP2014224123A (ja) 2014-12-04
BRPI0918103A2 (pt) 2016-07-05
KR101761324B1 (ko) 2017-07-25
WO2010071923A1 (en) 2010-07-01

Similar Documents

Publication Publication Date Title
HK1255046A1 (zh) 粒细胞巨噬细胞集落刺激因子的拮抗剂的用途
AU2012285875B2 (en) Use of c-Fms antagonists
HK1162335B (en) Pain treatment
HK1162335A (en) Pain treatment